Reduction of proteinuria by pioglitazone in patients with non-diabetic renal disease

Journal of Research in Medical Sciences

Volumn 16, Issue 11, 2011, Pages 1459-1465

  Shahidi, Shahrzad ^a   Pakzad, Bahram ^b   Mortazavi, Mojgan ^c   Akbari, Mojtaba ^a   Seirafian, Shiva ^a   Atapour, Abdolamir ^c   Saeidi, Samira Al ^a   Shayegannejad, Alireza ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c GONABAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Pioglitazone; Proteinuria; Renal disease; Thiazolidinediones

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; NITROGEN; PIOGLITAZONE; PROTEIN; UREA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MALE; PROTEIN URINE LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 82955240964     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11(Suppl 15): S1-86.
2. th ed. Boston: Little, Brown; 1988. p. 393-491.
3. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idi-opathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51(3): 901-7.
4. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17(5): 365-70.
5. Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L, et al. Rosiglitazone improves, while Glibencla-mide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44(2): 215-22.
6. Sarafidis PA, Lasaridis AN, Nilsson PM, Hitoglou-Makedou AD, Pagkalos EM, Yovos JG, et al. The effect of ro-siglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005; 18(2 Pt 1): 227-34.
7. Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002; 51(4): 403-8.
8. Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004; 53(11): 1473-9.
9. Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001; 18(4): 308-13.
10. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17(1): 7-12.
11. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC, et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999; 277(6 Pt 2): F966-F973.
12. Kincaid-Smith P, Fairley KF, Farish S, Best JD, Proietto J. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 2008; 13(1): 58-62.
13. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003; 52(8): 1943-50.
14. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357(9268): 1601-8.
15. Shahidi S, Pakzad B, Mortazavi M, Seirafian S, Akbari A, Atarpour A, et al. Effect of pioglitazone on proteinuria in non-diabetic renal patients: A self-control clinical trial. Journal of Isfahan Medical School 2010; 28(112): 632-9.
16. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, et al. Antihypertensive and vasculo- and reno-protective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997; 272(6 Pt 1): E989-E996.
17. Agarwal R, Saha C, Battiwala M, Vasavada N, Curley T, Chase SD, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005; 68(1): 285-92.
18. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59(5): 1899-910.
19. Haraguchi K, Shimura H, Onaya T. Suppression of experimental crescentic glomerulonephritis by peroxisome proli-ferator-activated receptor (PPAR) gamma activators. Clin Exp Nephrol 2003; 7(1): 27-32.
20. Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int Suppl 2004; (92): S45-S49.
21. Bakris GL. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep 2004; 6(5): 352-6.